Omer Khalid, MD
Gastroenterology · North Chesterfield, VANPI 1174565899
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,625 of the $81,871 with a category attached, or 80.2%. Gilead accounts for 65.8% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $26,805 and has fallen 95.6% since, to $1,167 in 2025. Among gastroenterology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 523 payments — averaging $156.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$54K
- AbbVie$24K
- Pfizer$514
- Bristol Myers Squibb$472
- Takeda Pharmaceuticals U.S.A., Inc.$443
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$431
- plus $2K from 27 others
Across 342 payments — averaging $3415.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$496K
- Boehringer Ingelheim International GmbH$357K
- GSK$128K
- Eli Lilly$74K
- Madrigal Pharmaceuticals$42K
- Bausch Health US, LLC$20K
- plus $51K from 5 others
What the payments were for
- Speaking & faculty fees$65,62580%
- Travel & lodging$6,7688%
- Food & beverage$9,47812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 59 | $53,889 |
| AbbVie(2 entities) | 240 | $23,932 |
| Pfizer | 29 | $514 |
| Bristol Myers Squibb | 31 | $472 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $443 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $431 |
| Johnson & Johnson | 21 | $404 |
| Sanofi | 15 | $399 |
| Ironwood Pharmaceuticals, Inc | 10 | $169 |
| QOL Medical, LLC | 7 | $135 |
| Braintree Laboratories, Inc. | 7 | $133 |
| Regeneron Healthcare Solutions, Inc. | 5 | $129 |
| Ardelyx, Inc. | 6 | $102 |
| Merck | 5 | $93 |
| Pharmacosmos Therapeutics Inc. | 3 | $80 |
| Apollo Endosurgery US Inc | 3 | $69 |
| Alnylam Pharmaceuticals Inc. | 4 | $64 |
| Ipsen Biopharmaceuticals, Inc | 2 | $61 |
| Shionogi Inc | 2 | $48 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Amgen | 1 | $33 |
| Enterra Medical, Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Medtronic | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Organon | 2 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Echosens North America, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,871 in reported general payments places this provider in the 95th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 40 | $33,830 |
| Colestipol Hcl | 20 | $2,439 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 39 | $2,434 |
| Omeprazole | 90 | $1,343 |
| Esomeprazole Magnesium | 20 | $830 |
| Pantoprazole Sodium | 65 | $772 |
| Mesalamine ErMesalamine | 12 | $678 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 48 | $665 |
| Dicyclomine Hcl | 17 | $517 |
| Azathioprine | 15 | $307 |
| Famotidine | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $23,932 | $33,83040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in North Chesterfield
- Larry ClarkLynchburg$1.2M
- Arun SanyalRichmond$855K
- Mitchell ShiffmanNewport News$635K
- Bryan SauerCharlottesville$540K
- Michael RyanNorfolk$335K
- Brian WentworthCharlottesville$276K
- Vanessa ShamiCharlottesville$210K
- Ali SiddiquiFairfax$167K
- Michael FuchsRichmond$126K
- Michael ManetasRichmond$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.